Hypoxia-inducible factors: central regulators of the tumor phenotype

Current Opinion in Genetics and Development

Volumn 17, Issue 1, 2007, Pages 71-77

  Gordan, John D ^a   Simon, M Celeste ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETERODIMER; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; VASCULOTROPIN;

ALPHA CHAIN; ANGIOGENESIS; BETA CHAIN; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL INVASION; ENZYME METABOLISM; GENE CONTROL; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; IONIZING RADIATION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN STABILITY; PROTEIN TARGETING; REVIEW; SOLID TUMOR; TUMOR DIFFERENTIATION;

CELL HYPOXIA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MODELS, BIOLOGICAL; NEOPLASMS; PHENOTYPE; PROTEIN SUBUNITS;

EID: 33846199233     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2006.12.006     Document Type: Review

References (81)

1. Wang G.L., and Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270 (1995) 1230-1237
2. Makino Y., Cao R., Svensson K., Bertilsson G., Asman M., Tanaka H., Cao Y., Berkenstam A., and Poellinger L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414 (2001) 550-554
3. Tian H., McKnight S.L., and Russell D.W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11 (1997) 72-82
4. Pugh C.W., and Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9 (2003) 677-684
5. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
6. Hu C.J., Iyer S., Sataur A., Covello K.L., Chodosh L.A., and Simon M.C. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1α) and HIF-2α in stem cells. Mol Cell Biol 26 (2006) 3514-3526
7. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., and Simon M.C. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol Cell Biol 23 (2003) 9361-9374
8. Maltepe E., Schmidt J.V., Baunoch D., Bradfield C.A., and Simon M.C. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386 (1997) 403-407
9. Keith B., Adelman D.M., and Simon M.C. Targeted mutation of the murine arylhydrocarbon receptor nuclear translocator 2 (Arnt2) gene reveals partial redundancy with Arnt. Proc Natl Acad Sci USA 98 (2001) 6692-6697
10. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
11. 2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
12. Bruick R.K., and McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294 (2001) 1337-1340
13. Yu F., White S.B., Zhao Q., and Lee F.S. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 98 (2001) 9630-9635
14. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
15. Mahon P.C., Hirota K., and Semenza G.L. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15 (2001) 2675-2686
16. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., and Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16 (2002) 1466-1471
17. KimWY, and Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 22 (2004) 4991-5004
18. Kondo K., Kim W.Y., Lechpammer M., and Kaelin Jr. W.G. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1 (2003) E83
19. Kondo K., Klco J., Nakamura E., Lechpammer M., and Kaelin Jr. W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 (2002) 237-246
20. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., and Klausner R.D. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 (2002) 247-255
21. Rankin E.B., Higgins D.F., Walisser J.A., Johnson R.S., Bradfield C.A., and Haase V.H. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol 25 (2005) 3163-3172
22. Lee S., Nakamura E., Yang H., Wei W., Linggi M.S., Sajan M.P., Farese R.V., Freeman R.S., Carter B.D., Kaelin Jr. W.G., et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8 (2005) 155-167. In this study, a novel, HIF-independent mechanism for VHL-disease associated pheochromocytoma is described.
23. Ryan H.E., Lo J., and Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17 (1998) 3005-3015
24. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., and Johnson R.S. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 60 (2000) 4010-4015
25. Acker T., Diez-Juan A., Aragones J., Tjwa M., Brusselmans K., Moons L., Fukumura D., Moreno-Murciano M.P., Herbert J.M., Burger A., et al. Genetic evidence for a tumor suppressor role of HIF-2α. Cancer Cell 8 (2005) 131-141
26. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
27. -/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27. Mol Cell Biol 25 (2005) 4565-4578
28. Mack F.A., Rathmell W.K., Arsham A.M., Gnarra J., Keith B., and Simon M.C. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 3 (2003) 75-88
29. Raval R.R., Lau K.W., Tran M.G., Sowter H.M., Mandriota S.J., Li J.L., Pugh C.W., Maxwell P.H., Harris A.L., and Ratcliffe P.J. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25 (2005) 5675-5686
30. Blouw B., Song H., Tihan T., Bosze J., Ferrara N., Gerber H.P., Johnson R.S., and Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4 (2003) 133-146
31. Chandel N.S., Maltepe E., Goldwasser E., Mathieu C.E., Simon M.C., and Schumacker P.T. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 95 (1998) 11715-11720
32. Hagen T., Taylor C.T., Lam F., and Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1α. Science 302 (2003) 1975-1978
33. Vaux E.C., Metzen E., Yeates K.M., and Ratcliffe P.J. Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain. Blood 98 (2001) 296-302
34. •].
35. •].
36. •], show a requirement for ROS in hypoxic HIF-α stabilization.
37. -/- mice are analyzed, showing a substantial accumulation or ROS, resulting in hypoxic HIF-α stabilization.
38. Jung C.R., Hwang K.S., Yoo J., Cho W.K., Kim J.M., Kim W.H., and Im D.S. E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat Med 12 (2006) 809-816. E2-EPF ubiquitin carrier protein is characterized as a novel upstream regulator of pVHL stability, identifying a mechanism of HIF upregulation that is likely to be important in multiple tumor types.
39. Wagner K.W., Sapinoso L.M., El-Rifai W., Frierson H.F., Butz N., Mestan J., Hofmann F., Deveraux Q.L., and Hampton G.M. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene 23 (2004) 6621-6629
40. Isaacs J.S., Jung Y.J., Mole D.R., Lee S., Torres-Cabala C., Chung Y.L., Merino M., Trepel J., Zbar B., Toro J., et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8 (2005) 143-153
41. Selak M.A., Armour S.M., MacKenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., Pan Y., Simon M.C., Thompson C.B., and Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7 (2005) 77-85
42. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., and Semenza G.L. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
43. Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., and Kaelin Jr. W.G. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4 (2003) 147-158
44. Koken M.H., Linares-Cruz G., Quignon F., Viron A., Chelbi-Alix M.K., Sobczak-Thepot J., Juhlin L., Degos L., Calvo F., and de The H. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 10 (1995) 1315-1324
45. Bernardi R., Guernah I., Jin D., Grisendi S., Alimonti A., Teruya-Feldstein J., Cordon-Cardo C., Simon M.C., Rafii S., and Pandolfi P.P. PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR. Nature 442 (2006) 779-785. The authors show that PML regulates HIF-α expression under hypoxic conditions through modulation of mTOR, providing mechanistic insight into translational control and an important tumor suppressor.
46. Wiesener M.S., Jurgensen J.S., Rosenberger C., Scholze C.K., Horstrup J.H., Warnecke C., Mandriota S., Bechmann I., Frei U.A., Pugh C.W., et al. Widespread hypoxia-inducible expression of HIF2α in distinct cell populations of different organs. FASEB J 17 (2003) 271-273
47. Ema M., Taya S., Yokotani N., Sogawa K., Matsuda Y., and Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 94 (1997) 4273-4278
48. -/- renal cell carcinoma cells. J Biol Chem 278 (2003) 44966-44974
49. Covello K.L., Kehler J., Yu H., Gordan J.D., Arsham A.M., Hu C.J., Labosky P.A., Simon M.C., and Keith B. HIF2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20 (2006) 557-570. By identifying and characterizing HIF-2α effects on Oct4, Covello and colleagues show a novel and unique role for HIF-2α in embryonic development, adult stem cell biology and tumor behavior.
50. Wang V., Davis D.A., Haque M., Huang L.E., and Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1α and hypoxia-inducible factor-2α in HEK293T cells. Cancer Res 65 (2005) 3299-3306
51. Baba M., Hirai S., Yamada-Okabe H., Hamada K., Tabuchi H., Kobayashi K., Kondo K., Yoshida M., Yamashita A., Kishida T., et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Oncogene 22 (2003) 2728-2738
52. Erler J.T., Bennewith K.L., Nicolau M., Dornhofer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., and Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440 (2006) 1222-1226. In a study utilizing primary patient samples and knockout mice, an essential role in metastasis is described for the HIF target lysyl oxidase.
53. Iyer N.V., Kotch L.E., Agani F., Leung S.W., Laughner E., Wenger R.H., Gassmann M., Gearhart J.D., Lawler A.M., Yu A.Y., et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12 (1998) 149-162
54. Compernolle V., Brusselmans K., Acker T., Hoet P., Tjwa M., Beck H., Plaisance S., Dor Y., Keshet E., Lupu F., et al. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8 (2002) 702-710
55. -/- mice. Nat Genet 35 (2003) 331-340
56. Tian H., Hammer R.E., Matsumoto A.M., Russell D.W., and McKnight S.L. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12 (1998) 3320-3324
57. Peng J., Zhang L., Drysdale L., and Fong G.H. The transcription factor EPAS-1/hypoxia-inducible factor 2α plays an important role in vascular remodeling. Proc Natl Acad Sci USA 97 (2000) 8386-8391
58. Yoshimura H., Dhar D.K., Kohno H., Kubota H., Fujii T., Ueda S., Kinugasa S., Tachibana M., and Nagasue N. Prognostic impact of hypoxia-inducible factors 1α and 2α in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 10 (2004) 8554-8560
59. Covello K.L., Simon M.C., and Keith B. Targeted replacement of hypoxia-inducible factor-1α by a hypoxia-inducible factor-2α knock-in allele promotes tumor growth. Cancer Res 65 (2005) 2277-2286
60. Denko N.C., Fontana L.A., Hudson K.M., Sutphin P.D., Raychaudhuri S., Altman R., and Giaccia A.J. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22 (2003) 5907-5914
61. Maina E.N., Morris M.R., Zatyka M., Raval R.R., Banks R.E., Richards F.M., Johnson C.M., and Maher E.R. Identification of novel VHL target genes and relationship to hypoxic response pathways. Oncogene 24 (2005) 4549-4558
62. Takeda N., Maemura K., Imai Y., Harada T., Kawanami D., Nojiri T., Manabe I., and Nagai R. Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1. Circ Res 95 (2004) 146-153
63. Chi J.T., Wang Z., Nuyten D.S., Rodriguez E.H., Schaner M.E., Salim A., Wang Y., Kristensen G.B., Helland A., Borresen-Dale A.L., et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3 (2006) e47
64. •], describe the mechanism whereby HIF inhibits aerobic metabolism under hypoxia, limiting oxygen consumption and ROS production.
65. •].
66. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., and Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425 (2003) 307-311
67. Leufgen H., Bihl M.P., Rudiger J.J., Gambazzi J., Perruchoud A.P., Tamm M., and Roth M. Collagenase expression and activity is modulated by the interaction of collagen types, hypoxia, and nutrition in human lung cells. J Cell Physiol 204 (2005) 146-154
68. Tai M.H., Chang C.C., Kiupel M., Webster J.D., Olson L.K., and Trosko J.E. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26 (2005) 495-502
69. Gustafsson M.V., Zheng X., Pereira T., Gradin K., Jin S., Lundkvist J., Ruas J.L., Poellinger L., Lendahl U., and Bondesson M. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9 (2005) 617-628. Here, Gustaffson and colleagues describe an important new mechanism for HIF-α effects on development. By modulating Notch activity, the HIF-α subunits can promote or block differentiation in a context-dependent fashion.
70. Wilson A., and Radtke F. Multiple functions of Notch signaling in self-renewing organs and cancer. FEBS Lett 580 (2006) 2860-2868
71. •], shows an important role for HIF-1α in modulating the activity of the c-Myc proto-oncogene.
72. ••].
73. Gasparini G., Longo R., Toi M., and Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2 (2005) 562-577
74. Kung A.L., Zabludoff S.D., France D.S., Freedman S.J., Tanner E.A., Vieira A., Cornell-Kennon S., Lee J., Wang B., Wang J., et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6 (2004) 33-43
75. Kong D., Park E.J., Stephen A.G., Calvani M., Cardellina J.H., Monks A., Fisher R.J., Shoemaker R.H., and Melillo G. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 65 (2005) 9047-9055
76. Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., Czernin J., and Sawyers C.L. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12 (2006) 122-127
77. Atkins M.B., Hidalgo M., Stadler W.M., Logan T.F., Dutcher J.P., Hudes G.R., Park Y., Liou S.H., Marshall B., Boni J.P., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
78. Moeller B.J., Cao Y., Li C.Y., and Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441. This study shows a new role for HIF-1α in tumor biology, showing that it substantially promotes p53 activity and cell death following ionizing radiation.
79. Tang N., Wang L., Esko J., Giordano F.J., Huang Y., Gerber H.P., Ferrara N., and Johnson R.S. Loss of HIF1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6 (2004) 485-495. With cre-loxP-mediated deletion of HIF-1α from endothelial cells, Tang and colleagues show that HIF-1α expression in endothelial cells is key in tumor vascularization.
80. Moeller B.J., Dreher M.R., Rabbani Z.N., Schroeder T., Cao Y., Li C.Y., and Dewhirst M.W. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8 (2005) 99-110
81. Holmquist-Mengelbier L., Fredlund E., Lofstedt T., Noguera R., Navarro S., Nilsson H., Pietras A., Vallon-Christersson J., Borg A., Gradin K., et al. Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype. Cancer Cell 10 (2006) 413-423. This study shows the importance of HIF-2α in an additional tumor type. Furthermore, it suggests that some of the differences between HIF-1α and HIF-2α are due to differential stability under moderate hypoxia rather than distinct target genes.